Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19 is a research paper published in JAMA Network Open (2023). On theSindex it has a DataRank of 0.490. It has been cited 11 times, with 5 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.373
From this paper's citation signal
Citation Network Contribution
0.117
From 4 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 5 citers.
NCATS NIH HHS
Grant: UL1 TR001881
NCATS NIH HHS
Grant: UL1 TR000124
NIAID NIH HHS
Grant: UM1 AI069412
NIAID NIH HHS
Grant: UM1 AI069432
NIAID NIH HHS
Grant: UM1 AI068634
NIAID NIH HHS
Grant: UM1 AI106701
NIAID NIH HHS
Grant: UM1 AI068636
NIAID NIH HHS
Grant: U01 AI068636
NIAID NIH HHS
Grant: UM1 AI069423
NIAID NIH HHS
Grant: UM1 AI069481
NIAID NIH HHS
Grant: UM1 AI069424
MeSH Terms